A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity.
Share and Follow

The Therapeutic Goods Administration has approved the first medicine to treat sleep apnoea.

Mounjaro, which has the active ingredient tirzepatide, is widely used to treat type 2 diabetes.

However, the TGA has today expanded the drug’s usage to include obstructive sleep apnoea for adults living with obesity.

A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity.
A medicine used to treat type 2 diabetes has now been approved for use in adults with obstructive sleep apnoea and obesity. (iStock)

This makes Mounjaro the first and only medicine for obstructive sleep apnoea in Australia.

The drug has not been listed on the Pharmaceutical Benefits Scheme and will only be available through private prescription.

Mounjaro can now be used to treat moderate-to-severe obstructive sleep apnoea in adults living with a body mass index (BMI) of 30 or more.

Mounjaro has been approved to treat obesity in Australia.
Mounjaro has been approved to treat sleep apnoea in adults living with obesity. (CNN)

Mounjaro cannot be used to treat type 1 diabetes, or by children and teenagers under 18 years old.

Side effects associated with Mounjaro can include an upset stomach, injection site-related side effects, and low blood sugar. 

Obstructive sleep apnoea is the most common of all sleeping disorders and is thought to affect around 780,000 Australian adults.

It occurs when a person’s upper airway becomes blocked, causing breathing to be repeatedly interrupted during sleep. 

Professor Brendon Yee is a respiratory and sleep physician at the Woolcock Institute of Medical Research who was involved in a clinical trial of Mounjaro for obstructive sleep apnoea.

Yee said the TGA decision was a “long-awaited development” in the field of sleep medicine.

“For the first time, people with weight-related obstructive sleep apnoea can be treated with a medicine that addresses the underlying cause of their condition,” Yee said. 

“This marks a significant milestone in the treatment of this debilitating sleep disorder.

“Obstructive sleep apnoea can affect anyone, and obesity is the single greatest cause of the condition.

“At least 70 per cent of people living with obstructive sleep apnoea also live with obesity.”

Share and Follow
You May Also Like
PM leads charm offensive as Wallabies clash with Fiji

Prime Minister takes on a friendly approach as Wallabies face off against Fiji

They are neighbours, friends and in many cases family, but now the…
This flood-hit community needed a miracle to save its rodeo. It found one

This community hit by floods needed a miracle to save its rodeo – and it found one

It’s the annual rodeo that puts the small farming community of Stonehenge,…
Desperate search for 27 missing girls after flood disaster

Search Intensifies for 27 Missing Girls Following Flood Catastrophe

At least 51 people, including 15 children, were killed, with most of…
Joshua Brown

Mother of child who was reportedly mistreated at daycare expresses that she is deeply distressed.

A mother has shared her anguish after learning her child was one…

Introducing a Revolutionary Tool to Combat Australia’s Leading Cause of Death

Lung cancer is Australia’s fifth most diagnosed cancer, but causes the greatest…
Premier's pledge after visiting fire-damaged synagogue

Leader’s promise after visiting synagogue damaged by fire

Victoria Premier Jacinta Allan has vowed to provide all necessary support to…

Understanding the Impact: Examining the Clinics Affected by Trump’s Actions

Fadumo (not her real name), a widowed mother of three, walked for…
Tammy Hembrow leaves fans confused as she's seen wearing her diamond wedding ring following split from husband Matt Zukowski

Tammy Hembrow wears wedding ring after breakup with Matt Zukowski – causing confusion among fans

Tammy Hembrow is heading for divorce after splitting from her husband of…